Get the Stockscreener App
1.03
3.00%
0.03
After Hours:
1.04
0.01
+0.97%
Phio Pharmaceuticals Corp stock is traded at $1.03, with a volume of 103.96K.
It is up +3.00% in the last 24 hours and down -3.74% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
See More
Previous Close:
$1.00
Open:
$0.9913
24h Volume:
103.96K
Relative Volume:
0.66
Market Cap:
$11.97M
Revenue:
-
Net Income/Loss:
$-10.93M
P/E Ratio:
-0.7164
EPS:
-1.4378
Net Cash Flow:
$-10.72M
1W Performance:
+1.98%
1M Performance:
-3.74%
6M Performance:
-8.04%
1Y Performance:
-57.26%
1-Day Range:
$0.9913
$1.035
1-Week Range:
$0.9913
$1.1001
52-Week Range:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.03 | 11.62M | 0 | -10.93M | -10.72M | -1.4378 |
VRTX
Vertex Pharmaceuticals Inc
|
476.31 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.12 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
859.43 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
184.97 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.26 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Enterprise value to EBITDA forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Price to book forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals (PHIO) Slips 1.92% as Stock Tests Key Support at $0.97Sign of Strength - dars.gov.et
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
PHIO Q1 2026 Earnings: EPS Misses Estimates as Biotech Continues Clinical DevelopmentAnalyst Earnings Estimate - dars.gov.et
PHIO PE Ratio & Valuation, Is PHIO Overvalued - Intellectia AI
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock - Investing.com
Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock By Investing.com - Investing.com Nigeria
[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity - Stock Titan
Form 4 Phio Pharmaceuticals Corp For: 29 June By Investing.com - Investing.com South Africa
PHIO: PH-762 achieved strong safety and efficacy, with INTASYL poised for broader clinical impact - TradingView
PHIO: PH-762 achieved 85% response with no serious adverse events; next trial planned for early next year - TradingView
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026 - TMX Newsfile
PHIO PHARMACEUTICALS CORP (PHIO) Stock Chart - ChartMill
Phio Pharmaceuticals (PHIO) Second Annual Centri Capital Conference Summary - Quartr
Phio Pharmaceuticals (PHIO) Life Sciences Virtual Investor Forum Summary - Quartr
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 - The National Law Review
PHIO Forecast — Price Target — Prediction for 2027 - TradingView
Phio Pharmaceuticals Corp. Actuals & Estimates (MUN:44R1) - TradingView
44R1 Forecast — Price Target — Prediction for 2027 - TradingView
Phio Pharmaceuticals begins commercial-scale production of PH-762 By Investing.com - Investing.com South Africa
Phio Pharmaceuticals begins commercial-scale production of PH-762 - Investing.com
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026 - The Des Moines Register
PHIO Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesOne-Time Loss Impact - dars.gov.et
PHIO Should I Buy - Intellectia AI
Phio CEO to pitch INTASYL cancer platform at investor forum June 25 - Stock Titan
Phio Pharmaceuticals Corp (PHIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Phio Pharmaceuticals Corp (PHIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Phio Pharmaceuticals Corp (PHIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Phio Pharmaceuticals Corp (PHIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Phio Pharmaceuticals Corp (PHIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Phio Pharmaceuticals Corp (PHIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Phio Pharmaceuticals Corp (PHIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Phio Pharmaceuticals Corp (PHIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Phio Pharmaceuticals Corp (PHIO) Institutional Confidence - TradingKey
PHIO Q1 2026 Earnings: EPS Miss Widens as Clinical-Stage Biotech Continues R&D InvestmentEarnings Sentiment Score - newsline.com
PHIO Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesDividend Earnings Report - newsline.com
PHIO Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Reports ResultsProfit Inflection Point - newsline.com
Number of shareholders of Phio Pharmaceuticals Corp. – MUN:44R1 - TradingView
Phio Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as R&D Spending IntensifiesEPS Growth Report - dars.gov.et
Phio Pharmaceuticals Slides 2.6% as Selling Pressure PersistsStock Analysis - dars.gov.et
Phio Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Biotech Reports No Revenue - The Legal Advocate
Phio Pharmaceuticals (PHIO) Edges Higher, Testing Key Resistance at $1.17Reversal Setup Alerts - newsline.com
PHIOPhio Pharmaceuticals Corp Short Interest - Finviz
Phio Pharmaceuticals Corp. (PHIO) Gains Ground: Approaching Key Resistance After Support BounceMomentum Trade - DonanımHaber
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phio Pharmaceuticals Corp Stock (PHIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 31 '25 |
Buy |
1.03 |
5,000 |
5,150 |
291,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
0.89%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):